General Information of Experiment

Probe Name P21  Probe Info 
Probe concentration 1 uM
Criteria Quantification: Probe vs (Probe+Competitor)
Quantitative Method
SILAC
Competitor Name P27  Competitor Info 
Competitor Concentration 10 uM
In Vivo Experiment Model Model Type Living cell
Derived Tissue Pancreas
Disease Model Pancreatic ductal adenocarcinoma [ICD-11:2C10]
Model Name Human pancreatic ductal adenocarcinoma cells (BxPC-3)

Interaction Altas of This Experiment [1]

Enzyme
Click to Show/Hide to Show 5 Protein Related to This Bioclass
Target ID Target Name Binding Ratio
 LDTP01675  Antiviral innate immune response receptor RIG-I (RIGI) 426.8
 LDTP12538  Ras-related protein Rab-6B (RAB6B) 7.0
 LDTP02021  Ornithine aminotransferase, mitochondrial (OAT) 2.0
 LDTP02095  Propionyl-CoA carboxylase alpha chain, mitochondrial (PCCA) 1.9
 LDTP02175  Epoxide hydrolase 1 (EPHX1) 1.3
Immunoglobulin
Click to Show/Hide to Show 1 Protein Related to This Bioclass
Target ID Target Name Binding Ratio
 LDTP01417  Contactin-5 (CNTN5) 11.2
Other
Click to Show/Hide to Show 5 Protein Related to This Bioclass
Target ID Target Name Binding Ratio
 LDTP03755  Keratin, type I cytoskeletal 9 (KRT9) 3.0
 LDTP11140  Peroxiredoxin-like 2A (PRXL2A) 2.5
 LDTP04500  Heterogeneous nuclear ribonucleoprotein M (HNRNPM) 1.9
 LDTP04880  Small ribosomal subunit protein uS10 (RPS20) 1.9
 LDTP01534  Luc7-like protein 3 (LUC7L3) 1.7

References

1 Integrated phenotypic screening and activity-based protein profiling to reveal potential therapy targets of pancreatic cancer. Chem Commun (Camb). 2019 Jan 31;55(11):1596-1599. doi: 10.1039/c8cc08753a.